8-K filed May 5, 2026, 7:59 PM ET ticker ADPT CIK 0001478320

earnings confidence high sentiment positive materiality 0.75

Adaptive Biotechnologies Q1 revenue $70.9M, up 35% YoY; MRD revenue up 53%; raises FY2026 MRD guidance to $260-270M

Adaptive Biotechnologies Corp

2026-Q1 EPS reported -$0.13 revenue$70,874,000

Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).
Net loss narrowed to $20.0M from $29.8M; adj. EBITDA loss $2.5M improved from $12.7M loss.
Raised FY2026 MRD revenue guidance to $260-270M (from $255-265M), implying 22-27% annual growth.
Recognized $9.0M in MRD pharma regulatory milestone revenue, first U.S. primary endpoint milestone.
Immune Medicine revenue $3.8M (-57% YoY); cash & equivalents $237.2M.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-206455
form_type: 8-K
ticker: ADPT
cik: 0001478320
company_name: Adaptive Biotechnologies Corp
filed_at: 2026-05-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.342020+00:00
generated_at: 2026-05-14T23:20:02.817042+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-206455
json_url: https://secwatch.observer/filing/0001193125-26-206455.json
markdown_url: https://secwatch.observer/filing/0001193125-26-206455.md
text_url: https://secwatch.observer/filing/0001193125-26-206455.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/0001193125-26-206455-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/adpt-20260505.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

2315d86724169f954dba5bf5b5e9fe0bcf0f020b

Adaptive Biotechnologies Corp updated its full year 2026 guidance (raised).

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

cbe4a044c641e9b722120794c06a84fafe1dce6c

Adaptive Biotechnologies Corp reported the quarter ended March 31, 2026 results: revenue $70.9 million, net income $20.0 million.

First Quarter 2026 Financial Results Revenue was $70.9 million for the quarter ended March 31, 2026, representing a 35% increase from the first quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended March 31, 2026, revenue for the current quarter increased 45% from the first quarter in the prior year. MRD revenue was $67.1 million for the quarter, representing a 53% increase from the first quarter in the prior year. Immune Medicine revenue was $3.8 million for the quarter, representing a 57% decrease from the first quarter in the prior year. Excluding revenue from the Genentech Agreement, Immune Medicine revenue for the quarter ended March 31, 2026 decreased 26% from the first quarter in the prior year. Operating expenses for the first quarter of 2026 were $90.1 million, compared to $82.0 million in the first quarter of the prior year, representing an increase of 10%. Interest and other income, net was

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

GME

GameStop Q1 record net income $389.6M, revenue up 14%, new $2B buyback

GameStop Corp. June 2, 2026, 4:43 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

Net sales were $835.3 million for the first quarter

Filing page SEC filing

GTLB

GitLab Q1 revenue $264M (+23% YoY); plans 14% workforce cut, $30-35M charges

Gitlab Inc. June 2, 2026, 4:17 PM ET earnings Items 2.02, 2.05, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

in such filing. --- EX-99.1 (EX-99.1) --- GitLab Reports First Quarter Fiscal Year 2027 Financial Results First Quarter Fiscal Year 2027 Highlights: • Total revenue of $264.2 million, up 23% year-over-year • GAAP operating margin of (6)%; non-GAAP operating margin of 14% • Operating cash flow of $149.2 million and non-GAAP adjusted free cash flow of $146.7

Filing page SEC filing

PETS

PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment

PETMED EXPRESS INC June 2, 2026, 4:15 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. • Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.

Filing page SEC filing

SPWH

Sportsman's Warehouse Q1 net sales up 2.8% to $256.1M; same-store sales +2.1%; net loss $21.8M

SPORTSMAN'S WAREHOUSE HOLDINGS, INC. June 2, 2026, 4:10 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

and generating positive free cash flow to further strengthen our balance sheet through debt reduction.” For the thirteen weeks ended May 2, 2026: • Net sales increased 2.8% to $256.1 million, compared to $249.1 million in the first quarter of fiscal year 2025. Performance was driven primarily by a 7.4% gain in Hunting and Shooting Sports, led by firearms, ammunition,

Filing page SEC filing

PANW

Palo Alto Networks Q3 revenue $3.0B (+31% YoY); NGS ARR $8.1B (+60% YoY)

Palo Alto Networks Inc June 2, 2026, 4:08 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

chief financial officer of Palo Alto Networks. Third Quarter Fiscal 2026 Financial Highlights • Total revenue for the fiscal third quarter 2026 grew 31% year over year to $3.0 billion. This includes $388 million from CyberArk and Chronosphere. • Next-Generation Security ARR for the fiscal third quarter 2026 grew 60% year over year to $8.1 billion. This

Filing page SEC filing

ULTA

Ulta Q1 net sales +11.1% to $3.16B, comps +5.3%; FY EPS guidance raised to $28.36-$28.80

Ulta Beauty, Inc. June 2, 2026, 4:06 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

compared to the same period ended May 3, 2025 : 13 Weeks Ended May 2, May 3, (Dollars in millions, except per share data) 2026 2025 Net sales $ 3,163.9 $ 2,848.4 Comparable sales 5.3% 2.9% Gross profit (as a percentage of net sales) 40.1% 39.1% Selling, general and administrative expenses $ 814.7 $ 710.6

Filing page SEC filing

YEXT

Yext Q1 FY27: Adj EBITDA margin 25%, ARR $440.8M; boosts buyback by $100M

Yext, Inc. June 2, 2026, 4:05 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

Exchange Act, except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Yext Announces First Quarter Fiscal 2027 Results – Revenue of $107.9 million – Net Income Per Share, basic, of $0.02 or non-GAAP Net Income Per Share of $0.15 – Adjusted EBITDA of $26.9 million, resulting in an Adjusted EBITDA margin of 25% – ARR of

Filing page SEC filing

YSWY

Yesway reports Q1 net income $30.2M, Adjusted EBITDA $59.2M; introduces FY2026 outlook

Yesway, Inc. June 2, 2026, 7:35 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.

Comparable filing

On June 2, 2026, Yesway, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-206455

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.